Evolabs Research: 18 Kovera certificates.
The lab's record shows 18 certificates printed for Evolabs Research, analysed between 31 Mar 2026 and 29 May 2026, covering 10 products. Median HPLC purity is 99.94%. Kovera graded 18 as a pass and 0 as a fail.
What the record shows
RETRIEVED 2 AUGUST 2026None of the 18 certificates meets our failure rules: no lab fail, no unconfirmed identity, no purity under 95% and no content under 90% of the label. 12 measured more than 110% of the label, which Kovera does not grade as a fail.
Kovera revised 7 of these certificates after first publication, under the same report number: KVR-2026-EE331E (revised by the lab 2026-05-30: purity 99.788% → 99.731%, content 9.68 → 10.76 mg); KVR-2026-DF4A78 (revised by the lab 2026-05-30: purity 99.564% → 99.537%, content 52.25 → 53.81 mg); KVR-2026-AEC9DB (revised by the lab 2026-05-30: purity 98.552% → 99.528%, content 11.06 → 11.33 mg); KVR-2026-9F405D (revised by the lab 2026-05-30: purity 99.364% → 99.771%, content 5.19 → 5.67 mg); KVR-2026-129E57 (revised by the lab 2026-05-30: purity 99.629% → 99.402%, content 508.65 → 543.18 mg); KVR-2026-019FBF (revised by the lab 2026-05-30: purity 99.511% → 99.671%, content 11.38 → 5.59 mg); KVR-2026-83D3C6 (revised by the lab 2026-06-10: purity 98.977% → 98.98%, content 11.59 → — mg). Why that matters is in our revisions analysis.
A certificate covers the sample the client sent, and the client decides which results go public. The figures are as published on 2 August 2026; check the lab's verify page for the current version before you rely on one.
Products tested
10 AS PRINTEDEvery certificate
NEWEST FIRST · 18 ROWS| Report | Product | Lot | Purity | % of label | Analysed | Result | Check |
|---|---|---|---|---|---|---|---|
| KVR-2026-EE331E | Tesamorelin | EVO5212026 | 99.731% | 107.6%10.76 of 10 mg | 29 May 2026 | PASSrevised by the lab 2026-05-30: purity 99.788% → 99.731%, content 9.68 → 10.76 mg | Kovera ↗our verifier → |
| KVR-2026-DF4A78 | GHK-Cu | EVO5212026 | 99.537% | 107.6%53.81 of 50 mg | 29 May 2026 | PASSrevised by the lab 2026-05-30: purity 99.564% → 99.537%, content 52.25 → 53.81 mg | Kovera ↗our verifier → |
| KVR-2026-AEC9DB | PT-141 | EVO5212026 | 99.528% | 113.3%11.33 of 10 mg | 29 May 2026 | PASSover 110% of labelrevised by the lab 2026-05-30: purity 98.552% → 99.528%, content 11.06 → 11.33 mg | Kovera ↗our verifier → |
| KVR-2026-9F405D | BPC-157 | EVO5212026 | 99.771% | 113.4%5.67 of 5 mg | 29 May 2026 | PASSover 110% of labelrevised by the lab 2026-05-30: purity 99.364% → 99.771%, content 5.19 → 5.67 mg | Kovera ↗our verifier → |
| KVR-2026-129E57 | NAD+ | EVO5212026 | 99.402% | 108.6%543.18 of 500 mg | 29 May 2026 | PASSrevised by the lab 2026-05-30: purity 99.629% → 99.402%, content 508.65 → 543.18 mg | Kovera ↗our verifier → |
| KVR-2026-019FBF | Semax | EVO5212026 | 99.671% | 111.8%5.59 of 5 mg | 29 May 2026 | PASSover 110% of labelrevised by the lab 2026-05-30: purity 99.511% → 99.671%, content 11.38 → 5.59 mg | Kovera ↗our verifier → |
| KVR-2026-83D3C6 | MOTS-c | EVO5212026 | 98.98% | 116.3%11.63 of 10 mg | 23 May 2026 | PASSover 110% of labelrevised by the lab 2026-06-10: purity 98.977% → 98.98%, content 11.59 → — mg | Kovera ↗our verifier → |
| KVR-2026-FC7E39 | Tirzepatide | 04042026 | 99.932% | 117.6%23.52 of 20 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-E78C2E | Semaglutide | 04042026 | 99.962% | 106.1%10.61 of 10 mg | 31 Mar 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-D98793 | Semaglutide | 04042026 | 99.984% | 109.6%32.89 of 30 mg | 31 Mar 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-CE4F8D | Semaglutide | 04042026 | 99.972% | 116.6%5.83 of 5 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-BB05AC | Retatrutide | 04042026 | 99.938% | 111.4%5.57 of 5 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-987423 | Retatrutide | 04042026 | 99.943% | 115.8%23.16 of 20 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-9518F7 | Tirzepatide | 04042026 | 99.988% | 110.8%5.54 of 5 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-8EB1C8 | Tirzepatide | 04042026 | 99.981% | 118.2%11.82 of 10 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-7F44C0 | Retatrutide | 04042026 | 99.957% | 115.1%34.54 of 30 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-44488B | Semaglutide | 04042026 | 99.923% | 109.8%21.97 of 20 mg | 31 Mar 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-28B13A | Retatrutide | 04042026 | 99.969% | 118.2%11.82 of 10 mg | 31 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |